Table 1 Clinicopathological characteristics
Metastatic recurrence cohort (n = 62) | n (%) |
|---|---|
Age, mean (range) | 46 (31–80) |
Subtypes at primary diagnosis | |
 ER+/HER2− | 38 (61%) |
 ER+/HER2+ | 13 (21%) |
 ER+/HER2 unknown | 11 (18%) |
T stage at primary diagnosis | |
 T0 - DCIS | 2 (3%) |
 T1 | 12 (20%) |
 T2 | 33 (53%) |
 T3 | 7 (11%) |
 T4 | 3 (5%) |
 NA | 5 (8%) |
LN+ at primary diagnosis | |
 Negative | 10 (16%) |
 Positive | 44 (71%) |
 NA | 8 (13%) |
Chemotherapy for primary breast cancer | |
 Adjuvant | 24 (38%) |
 Neoadjuvant | 26 (42%) |
Endocrine treatments | |
 Neoadjuvant | 2 (3%) |
 Adjuvant TAM only | 47 (76%) |
 Adjuvant AI/AI + TAM | 14 (23%) |
 Advanced TAM only | 3 (5%) |
 Advanced AI/AI + TAM | 23 (37%) |
Median follow-up from primary diagnosis, median years (range) | 9.4 (3.3–27.7) |
Median follow-up from metastasis, years (range) | 3.9 (0.1–15.5) |